Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1613
This examiner grants 16% of resolved cases
Chasity Paige Janosko, an examiner in Art Unit 1613, presents a very challenging environment with an allowance rate of only 15.9 percent. Across 44 resolved cases in Tech Center 1600, this 15.9 percent rate indicates that the vast majority of applications are rejected. This is a difficult art unit for applicants, requiring a rigorous approach to the 44 cases in this portfolio.
However, the interview lift is a remarkable 63.6 percent. This 63.6 percent figure suggests that interviews are an essential tool for overcoming the 15.9 percent baseline. For the 44 cases resolved, direct communication with Chasity Paige Janosko was the most effective way to achieve an allowance. Practitioners should prioritize interviews to leverage this 63.6 percent lift and improve their odds.
The median time to allowance is 1244 days for the successful cases. This 1244-day pendency, combined with the 15.9 percent allowance rate, means that applicants must be prepared for a long and difficult process. The 63.6 percent interview lift is the only significant factor that improves the odds of success within the 1244-day window. The 1244-day metric is a critical baseline for planning.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18042424 | SILK PARTICLES ENCAPSULATING OXYGEN CARRIERS AS ARTIFICIAL BLOOD SUBSTITUTE | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18459442 | CELLULOSE PARTICLE | Non-Final OA | FUJIFILM Business Innovation Corp. |
| 17892353 | ORAL CARE COMPOSITIONS FOR GUM HEALTH | Non-Final OA | The Procter & Gamble Company |
| 17892387 | ORAL CARE COMPOSITIONS FOR GUM HEALTH | Non-Final OA | The Procter & Gamble Company |
| 18972793 | USE OF BOTULINUM TOXINS FOR THE TREATMENT OF PLATYSMA PROMINENCE | Non-Final OA | Allergan, Inc. |
| 18019609 | AGROCHEMICAL FORMULATIONS | Non-Final OA | BASF SE |
| 18906654 | Use of Branched Medium-Chain Glycerol Ethers as Active Antidandruff Ingredients | Non-Final OA | Henkel AG & Co. KGaA |
| 18833739 | COMPOSITIONS COMPRISING A NON-BIOABSORBABLE POLYMER AND METABOLIC INHIBITOR | Non-Final OA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 17907603 | PRECISION DELIVERY OF MULTI-SCALE PAYLOADS TO TISSUE-SPECIFIC TARGETS IN PLANTS | Final Rejection | MASSACHUSETTS INSTITUTE OF TECHNOLOGY |
| 18978032 | DISSOLVABLE POLYMERIC OCULAR INSERT FOR DRUGS DELIVERY | Non-Final OA | Alcon Inc. |
| 18282663 | CONCENTRATED COMPOSITION AND USES OF SAME | Final Rejection | Johnson & Johnson Consumer Inc. |
| 18035832 | Intradermal Delivery of Extracellular Vesicle-Encapsulated Curcumin Using Dissolvable Microneedle Arrays | Final Rejection | Carnegie Mellon University |
| 17606817 | NEW DELIVERY SYSTEM FOR SPECIFIC WATER-SOLUBLE VITAMINS | Final Rejection | DSM IP ASSETS B.V. |
| 18042509 | ULTRAVIOLET-ABSORPTIVE NANOPARTICLES AND MICROPARTICLES FOR INTRADERMAL USE | Final Rejection | THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate |
| 17792968 | COMPOSITIONS AND METHODS FOR CONTROLLED RELEASE OF TARGET AGENT | Non-Final OA | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY |
| 18275622 | ACTIVE AGENT-RELEASING HYALURONIC ACID VEHICLE | Final Rejection | Ariel Scientific Innovations Ltd. |
| 17637315 | COMPOSITION COMPRISING AT LEAST ONE ALKOXYSILANE OF FORMULA (I), AT LEAST ONE ALKOXYSILANE OF FORMULA (II), AT LEAST ONE NONAMINO SILICONE, AND OPTIONALLY PIGMENTS AND/OR DIRECT DYES | Final Rejection | L'OREAL |
| 17908350 | OIL-IN-WATER EMULSION COMPOSITION | Non-Final OA | Shiseido Company, Ltd. |
| 18041300 | SANITIZER COMPOSITION IN EMULSION FORMULATION | Final Rejection | Amorepacific Corporation |
| 18260101 | NATURAL OIL-BASED COMPOSITION THAT MIMICS PETROLATUM AND METHOD OF MAKING SAME | Non-Final OA | CARGILL, INCORPORATED |
| 17907595 | SKIN TREATMENT METHOD | Final Rejection | Kao Corporation |
| 17299205 | PROCESS FOR RESHAPING KERATIN FIBERS | Final Rejection | KAO GERMANY GMBH |
| 18842795 | SURFACE-TREATED ZINC OXIDE PARTICLES, DISPERSION LIQUID, COSMETIC MATERIAL, METHOD FOR PRODUCING SURFACE-TREATED ZINC OXIDE PARTICLES | Non-Final OA | SUMITOMO OSAKA CEMENT CO., LTD. |
| 18893942 | KNEE IMPLANT | Non-Final OA | Duke University |
| 18127373 | SUBSTITUTED TOLYL FUNGICIDES | Non-Final OA | FMC CORPORATION |
| 18264296 | COMPOSITIONS COMPRISING A MULTI-TAIL SURFACTANT AND A CATIONIC POLYMER AND USES | Non-Final OA | SPECIALITY OPERATIONS FRANCE |
| 18264301 | MULTIPHASIC LIQUID COMPOSITIONS FOR IMPROVED DEPOSITION OF ACTIVE INGREDIENTS | Non-Final OA | SPECIALITY OPERATIONS FRANCE |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy